Quick Answer
Q32 Bio Inc. reported Revenue (ASC 606) of $1.16 million for fiscal year 2023.
Q32 Bio Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2023 | $1.16M | -64.0% |
| 2022 | $3.21M | -90.6% |
| 2021 | $33.97M | +1157.3% |
| 2020 | $2.70M | +62.2% |
| 2019 | $1.67M | -68.7% |
| 2018 | $5.32M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $0.00 | -100.0% | -100.0% |
| June 30, 2023 | $354.0K | -55.9% | -55.9% |
| March 31, 2023 | $802.0K | +0.0% | +0.0% |
| September 30, 2022 | $802.0K | -52.2% | +0.0% |
| June 30, 2022 | $802.0K | -63.3% | +0.0% |
| March 31, 2022 | $802.0K | -97.3% | -52.2% |
| September 30, 2021 | $1.68M | +195.8% | -23.3% |
| June 30, 2021 | $2.19M | +285.7% | -92.5% |
- Q32 Bio Inc. showed a decrease of -64.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2018–2023 period, Q32 Bio Inc.’s revenue (asc 606) has declined by 78.3% (from $5.32 million to $1.16 million).
- The most recent figure is from Q32 Bio Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 13, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: